Caribou Biosciences' Co-Founder Dr. Jennifer Doudna And Chairman Of The Board Rodolphe Barrangou Selected For 2016 Canada Gairdner Awards

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a developer of CRISPR technologies for precision cell engineering, announced today that co-founder Jennifer Doudna, Ph.D., and Rodolphe Barrangou, Ph.D., M.B.A., Chairman of Caribou’s Board of Directors, have been named as two of the winners of the 2016 Canada Gairdner Awards for their contributions in CRISPR-Cas characterization and gene editing. The Canada Gairdner Awards are among the world's most esteemed medical research prizes and recognize and reward the achievements of medical researchers whose work contributes significantly to improving the quality of human life.

“We are delighted that Jennifer's and Rodolphe's visionary work and accomplishments are being recognized with this highly prestigious award”

"We are delighted that Jennifer's and Rodolphe's visionary work and accomplishments are being recognized with this highly prestigious award," said Rachel Haurwitz, Ph.D., President and Chief Executive Officer and co-founder of Caribou. "Their pioneering discoveries and continued pivotal efforts are helping to quickly transform the vast potential of CRISPR-Cas gene editing into reality. We continue to be deeply honored to have them serve central roles in both the creation and advancement of our organization."

Dr. Doudna, the Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, Professor of Molecular and Cell Biology and Professor of Chemistry at UC Berkeley and Investigator of the Howard Hughes Medical Institute, was recognized for her work in the development of CRISPR-Cas as a genome editing tool for eukaryotic cells.

Dr. Barrangou, an Associate Professor in the Department of Food, Bioprocessing and Nutrition Sciences at North Carolina State University, a NC State University Scholar, and the Todd R. Klaenhammer Distinguished Scholar in Probiotics Research, was recognized for his work in establishing and characterizing CRISPR-Cas bacterial immune defense system.

Additional information on the Canada Gairdner Awards and the selections of Dr. Doudna and Dr. Barrangou can be found at

About Caribou Biosciences, Inc.
Caribou Biosciences, Inc. is a developer of technology-based solutions for cellular engineering and analysis based on CRISPR systems. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. For more information, visit and follow @CaribouBio. "Caribou Biosciences" and the Caribou logo are trademarks of Caribou Biosciences, Inc.


Feinstein Kean Healthcare
Greg Kelley, 404-836-2302
Senior Vice President

Back to news